A phase III trial of FMX103 (minocycline) for the treatment of moderate-to-severe papulopustular rosacea.
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 27 Jun 2018
At a glance
- Drugs Minocycline (Primary)
- Indications Rosacea
- Focus Therapeutic Use
- Acronyms FX2016-12
- 27 Jun 2018 According to a Foamix media release, patient enrolment in this study has been completed and last patient has been dosed. Top-line results are expected in the fourth quarter of this year.
- 27 Jun 2018 Status changed from recruiting to active, no longer recruiting, according to the Foamix media release.
- 12 Jun 2017 Status changed from not yet recruiting to recruiting according to a Foamix media release.